Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)

Summary

Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year. Despite recent scientific advances in acute ischemic stroke treatment in recent decades,consensus treatment of all guidelines is still ASA

Timeline

Start

2020-08-22

Primary completion

2023-04-10

Completion

2023-04-30

Publications

• Ghazaeian M, Ramzanpour F, Sharifi-Razavi A. Aspirin plus rivaroxaban efficacy and safety in embolic stroke of undetermined source: A randomized, placebo-controlled, outcome assessor-blind, feasibility study. Clin Neurol Neurosurg. 2025 Mar;250:108813. doi: 10.1016/j.clineuro.2025.108813. Epub 2025 Feb 28.

Drugs

Indications